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Transplantation of human hematopoietic stem cells into severely
immunocompromised newborn mice allows the development of
a human hematopoietic and immune system in vivo. NOD/scid/γc−/−
(NSG) and BALB/c Rag2−/−γc−/− mice are the most commonly
used mouse strains for this purpose and a number of studies have
demonstrated the high value of these model systems in areas
spanning from basic to translational research. However, limited
cross-reactivity of many murine cytokines on human cells and re-
sidual host immune function against the xenogeneic grafts results
in defective development and maintenance of human cells in vivo.
Whereas NSG mice have higher levels of absolute human engraft-
ment than similar mice on a BALB/c background, they have a
shorter lifespan and NOD ES cells are unsuitable for the complex
genetic engineering that is required to improve human hemato-
poiesis and immune responses by transgenesis or knockin of hu-
man genes. We have generated mice that faithfully express a
transgene of human signal regulatory protein alpha (SIRPa), a re-
ceptor that negatively regulates phagocytosis, in Rag2−/−γc−/−
mice on a mixed 129/BALB/c background, which can easily be ge-
netically engineered. These mice allow signiﬁcantly increased en-
graftment andmaintenance of human hematopoietic cells reaching
levels comparable to NSG mice. Furthermore, we found improved
functionality of the human immune system in these mice. In sum-
mary, hSIRPa-transgenic Rag2−/−γc−/− mice represent a unique
mouse strain supporting high levels of human cell engraftment,
which can easily be genetically manipulated.
CD34+ cell | xenorejection
Mice play a crucial role as the prime model organism to studymany aspects of development and function in hematology
and immunology. However, their habitats and pathogens that
shape and constantly challenge the immune system have di-
verged between species, resulting in the fact that genes related to
immunity, together with genes involved in reproduction and ol-
faction, are the most divergent between the two species (1). Mice
rendered genetically suitable to support human cells and tissues
have become a favorite model bridging the gap between mouse
models and studies in humans (2–4). Particularly, mice that re-
constitute a functional human immune system after engraftment
of hematopoietic stem and progenitor cells (HSPCs) are of high
interest to study vaccine candidates and the biology of pathogens
restricted to humans in vivo. To achieve efﬁcient xenotransplan-
tation, mice lacking an adaptive immune system and natural
killer (NK) cells have been successfully developed in the last
years and the major models differ mainly in the background
strains used. The ﬁrst one employs the BALB/c Rag2−/−γc−/−
(DKO) mice, and neonatal intrahepatic HSPC transfer (5, 6). A
second model reconstitutes instead NOD/scid/γc−/− (NSG) mice
by i.v. or intrahepatic injection of human HSPCs (7–9). After
transfer into these mice, human HSPCs can develop into most of
the hematopoietic lineages and the human chimerism is main-
tained for several months (5, 8). Overall the composition of
engrafted cells is similar in these models but higher human en-
graftment levels were obtained in NOD-based models (10). This
advantage is thought to be caused at least partially by a poly-
morphism in the gene encoding the inhibitory receptor signal
regulatory protein alpha (SIRPa) (11).
SIRPa is a transmembrane protein containing three Ig-like
domains in its extracellular region and putative tyrosine phos-
phorylation sites in its cytoplasmic region (12). SIRPa is strongly
expressed in neurons and in macrophages, dendritic cells, and
neutrophils. The ligands of SIRPa are CD47 and surfactant A
and surfactant D and their binding to the receptor induces the
recruitment of phosphatases SHP-1 and SHP-2 to the plasma
membrane. In phagocytic cells, this recruitment negatively reg-
ulates phagocytosis upon binding to its ligands (13). CD47 is
ubiquitously expressed in all cells of the body, including all lin-
eages of hematopoietic cells. The inhibitory signaling via CD47-
SIRPa ligation has important consequences in vivo because upon
transfer into WT mice, CD47−/− cells are rapidly cleared by
splenic red pulp macrophages (14). Subsequently it was recog-
nized that the regulation of CD47 expression plays important
functions in such diverse biological processes as cell migration,
the regulation of the erythrocyte life span, and HSC circulation
(14–16). Whereas it had been recognized that mouse phagocytes
regulate human cell and tissue transplantation into mice (17–19),
it has been recently demonstrated that, due to allelic variation,
partial engagement of NOD SIRPa but not C57BL6 SIRPa
on respective phagocytes by human CD47 leads to decreased
phagocytosis of human cells in vitro (11, 20). Given the above
discussed additional residual xenogeneic engraftment impair-
ment, we hypothesized that expression of hSIRPa on mouse
macrophages would lead to decreased phagocytosis of human
CD47-expressing cells (14, 21, 22). Thus, to create an improved
platform for future generations of humanized mice, we have
generated human SIRPa transgenic mice faithfully expressing
the receptor using F1 129/BALB/c Rag2+/−γcy/− ES cells, which
allow easy and rapid genetic modiﬁcations.
Results
hSIRPa Is Faithfully Expressed and Functional in hSIRPa-Trangenic
Mice.A bacterial artiﬁcial chromosome encompassing the coding
region of human SIRPa was identiﬁed and engineered to contain
a eukaryotic selection marker to allow transgenesis in ES cells.
We generated hSIRPa-transgenic Rag2−/−γc−/− (hSIRPa-DKO)
mice expressing the human transgene under the human regula-
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tory elements after targeting an ES cell line (F1 129/BALB/c
Rag2+/−γcy/−), which can easily be genetically manipulated (23,
24). Upon obtaining several lines of hSIRPa-expressing mice, the
expression levels of hSIRPa were analyzed on mouse CD45+
cells by ﬂow cytometry. hSIRPa was faithfully expressed in BAC-
transgenic mice as cells expressing mouse SIRPa expressed also
hSIRPa (Fig. 1A and Fig. S1A). In contrast, no hSIRPa expres-
sion was detected on cells not expressing mouse SIRPa. hSIRPa-
DKO mice had similar numbers of leukocytes, including neu-
trophils and monocytes, in the blood and did not show any signs
of thrombocytopenia and anemia, which is a prominent feature
in SIRPa−/− mice (25) (Fig. S1 B–D). This indicates that expres-
sion of hSIRPa does not interfere with the function of mSIRPa
in vivo. Clearance of erythrocytes is regulated in vivo in a CD47-
SIRPa–dependent manner (14). To evaluate, if hSIRPa was
functional on mouse cells, human erythrocytes that express CD47
were injected into DKO, hSIRPa-DKO, and NSG mice and their
clearance was monitored. Similarly to NSG mice, signiﬁcantly
higher numbers of erythrocytes were present in the blood of
hSIRPa-DKO mice compared with DKO mice, indicating that
hSIRPa is functional in the mouse in vivo, negatively regulating
phagocytosis and thus elimination of human CD47-expressing
cells (Fig. 1 B and C).
Multilineage Engraftment in the Blood of hSIRPa-DKO Mice. To test
whether hSIRPa expression in immunocompromised mice would
lead to increased engraftment levels after human CD34+ cell
transplantation, we next transplanted newborn irradiated DKO,
hSIRPa-DKO, and NSG mice with human fetal liver-derived
CD34+ cells, a population highly enriched in HSPCs. A total of
88% of engrafted hSIRPa-DKO mice had greater than 1% hu-
man CD45+ cells in the peripheral blood, which is similar to
NSG mice, whereas only 52% of DKO surpassed this value
(Table S1). Compared with DKO mice, NSG mice had signiﬁ-
cantly higher frequencies of human CD45+ cells in the blood of
engrafted mice, 10–12 wk after transplantation (6.6% compared
with 17.6%, P < 0.001) (Fig. 2B). Strikingly, hSIRPa-DKO had
increased frequencies of human CD45+ cells compared with
DKO mice (23.3% compared with 6.6%, P < 0.001) reaching
levels at least similar to NSG mice (Fig. 2B). We furthermore
compared DKO and hSIRPa-DKO mice to NRG mice (26).
NRG mice had signiﬁcantly higher engraftment levels compared
with DKO (29.6% compared with 6.6%, P < 0.001), and similar
high engraftment levels as NSG and hSIRPa-DKO. Hence, no
signiﬁcant differences were found between hSIRPa-DKO mice
and NOD-based strains. As previously described, we were able to
detect in all models multilineage development of human CD45+
cells in vivo (Fig. 2 C–E and Fig. S2). When these mice were
analyzed in detail, the overall composition of human CD45+
cells regarding B cells and myeloid cells was similar in all mouse
strains (Fig. 2 C–E). Notably, an increase in T cell frequency in
the blood of hSIRPa-DKO mice compared with DKO and NSG
mice was detected, which was not seen when hSIRPa-DKO mice
were compared with NRG mice (hSIRPa, 40% compared with
DKO, 29.3%; NSG, 19.6%; and NRG, 45%, respectively).
Enhanced Human Cell Engraftment in the Bone Marrow and the
Periphery of hSIRPa Mice. Next we analyzed bone marrow, spleen,
and thymus 12–14 wk posttransplantation to characterize whether
similar differences could be found in these hematopoietic organs.
In the bone marrow, hSIRPa-DKO and NSG and NRG mice
(which were analyzed together in the subsequent experiments)
contained signiﬁcantly higher frequencies and total numbers of
hCD45+ cells than DKO mice (Fig. 2 G and H). As observed in
blood, the composition of hCD45+ in the bone marrow was not
different between the different strains with similar frequencies
of CD34+ HSPCs, CD19+ B cells, CD33+SSClow monocytes/den-
dritic cells, and CD33intCD66+SSChigh granulocytes. Neverthe-
less, due to increased total numbers of hCD45+ cells, the
numbers of all subsets including CD34+ and CD34+CD38− cells,
a population enriched for human early progenitor cells andHSCs,
were signiﬁcantly increased in hSIRPa-DKOmice (Fig. 2 I and J).
Further analysis showed that also frequencies of human CD45+
cells in the spleen were increased in SIRP-DKO mice, reaching
levels observed in NSG and NRG mice (Fig. 3 A and B). Besides
an increase in the frequency of CD3−NKp46+ cells, which include
predominantly NK cells but also lymphoid tissue inducer cells, in
hSIRPa-DKO mice (2.8% vs. 1.3%, P < 0.03), overall composi-
tion was not signiﬁcantly different between DKO and hSIRPa -
DKO mice (Fig. 3 D and E and Fig. S3). Notably, in contrast
to the peripheral blood NSG/NRG mice had slightly higher
CD3+ T cell numbers, but lower CD19+ B cell numbers com-
pared with hSIRPa-DKO mice, whereas overall hCD45+ num-
bers were similar. In all groups of mice, the ratio between CD4+
and CD8+ T cells was similar to the ratio found in humans
(Fig. S3). In all mouse strains, CD4+ T cells consisted of naïve
cells (CCR7+CD45RO−) and subsets of memory cells (CCR7+/−
CD45RO+) with a signiﬁcant variability between mice (Fig. S3).
In the thymus, hSIRPa-DKO mice had higher numbers of total
hCD45+ cells and CD4+CD8+ thymocytes compared with the
DKO mice (Fig. 3 G and H). Cell numbers were also higher
than we observed in NSG mice, indicating that additional strain-
speciﬁc factors or even better interaction of human CD47 and
human SIRPa compared with human CD47 and NOD-SIRPa
might inﬂuence T cell development and maintenance in this
inbred strain.
Enhanced Human Cell Maintenance in hSIRPa Mice. The duration of
human hematopoiesis after engraftment of human stem and
progenitor cells is limited as demonstrated by relatively low
recovery of cells that are able to efﬁciently engraft secondary
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Fig. 1. hSIRP is faithfully expressed and is functional in BAC-transgenic
mice. (A) Expression of mouse and human SIRPa in the blood was analyzed
by FACS staining in hSIRPa-transgenic (gray solid line) and control (black
solid line) mice. Isotype staining for hSIRP is shown as dashed line. (B and C)
Human erythrocytes were transferred in Rag2−/−γc−/− (−hSIRPa), hSIRPa+
Rag2−/−γc−/− mice (+hSIRPa), and NSG mice. Their clearance was monitored
by FACS staining for hGPA-expressing cells in the peripheral blood of mice.
Data are a summary of two independent experiments with a total of 10 mice
per group. *P < 0.01 by one-way ANOVA test.
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recipients in vivo (23, 27). Accordingly, we observed a steady
decrease of human cell numbers in the bone marrow. At 23–26
wk, numbers of hCD45+ were around one-third of the numbers
after 12–14 wk in DKO and hSIRPa-DKO mice and NSG/NRG
mice (Fig. S4 A and B). Cell numbers further decreased with
time and hCD45+ cells could be recovered in signiﬁcant numbers
only from hSIRPa-DKO after 35–37 wk (Fig. S4 A and B). We
were unable to analyze NSG mice at this late time point, because
of a high mortality that became apparent beyond 6 mo (Table
S2), which has also been reported previously (28). In the spleen,
we observed a similar trend with cell numbers declining in all
strains of mice from 3 to 6 mo (Fig. S4 C and D). Notably, in
hSIRPa-DKO, numbers in the spleen did not decline much
further between 6 and 9 mo, indicating that differentiated cells
can persist in these mice (Fig. S4 C and D). At 24 and 36 wk
postengraftment, hSIRPa-DKO mice contained on average 3.3-
fold and 5.1-fold more human CD45+ cells in the spleen than
DKO mice, respectively. At later time points, the frequency of
T cells increased, whereas the frequency of B cells decreased
(Fig. S4 E–H). In summary, these results indicate that hSIRPa-
DKO mice lose the ability for human hematopoiesis in a similar
way to DKO mice, likely due to the loss of HSPCs; however,
they have a superior capacity to maintain differentiated cells in
the periphery.
Increased Antigen-Speciﬁc Humoral Immune Responses in hSIRPa-
Transgenic Mice. To test whether the increase of human immune
cells translated into quantitative and qualitative changes of the
human adaptive immune system in vivo, we ﬁrst analyzed total
levels of human immunoglobulins in mice 12–16 wk posten-
graftment. Indeed, compared with DKO mice, hSIRPa-DKO
mice had increased levels of human IgM (185 ± 55 μg/mL vs.
24 ± 9 μg/mL, P < 0.03, mean ± SEM) and IgG (113 ± 36 μg/mL
vs. 26 ± 6 μg/mL, P < 0.02) in the plasma (Fig. 4 A and B).
Accordingly, a higher number of human IgG-producing cells
were detected in the spleen of hSIRPa-DKOmice (Fig. 4C). This
correlated with an increased frequency of CD27+ memory B
cells in the spleen (Fig. S5). Next, DKO and hSIRPa-DKO mice
were immunized with a protein antigen (ovalbumin, OVA)
mixed with an adjuvant (complete Freund’s adjuvant) to assess
the de novo development of antigen-speciﬁc immune responses.
Because most studies using CD34+ cell-engrafted mice reported
only low levels of antigen-speciﬁc immune responses, we decided
to use this potent adjuvant to provide the strongest conditions
for priming of de novo immune responses (7, 8, 29). Mice were
boosted 2 wk later with OVA/incomplete Freund’s adjuvant and
bled 10 d after the boost. Whereas nonimmunized DKO and
hSIRPa-DKO did not have signiﬁcant levels of anti-OVA anti-
bodies (IgM, IgG), we detected anti-OVA IgM in 66.6% (12 of
18) of DKO mice and in 88% (21 of 24) of hSIRPa-DKO mice
(Table S3). Using endpoint dilution of the sera of immunized
mice, antibody titers were determined for IgM and IgG from
individual mice. For anti-OVA IgM, there was no signiﬁcant
difference in the frequency of mice responding between the two
groups, nevertheless hSIRPa-DKO mice had increased antibody
titers compared with DKO mice (Fig. 4 D–F). When antigen-
speciﬁc IgG were analyzed, a more striking difference was dis-
cernible. In only 2 out of 18 (11%) DKO mice could antigen-
speciﬁc IgG be detected, whereas IgG was detectable in 16 of
24 (66.6%) hSIRPa-DKO mice (Table S3 and Fig. 4 G–I). In
summary, upon immunization we observed signiﬁcant difference
in the levels of speciﬁc antibody responses as evidenced by the
higher IgM titers in hSIRPa-DKO mice and a higher frequency
of hSIRPa-DKO mice producing antigen-speciﬁc IgG. This will
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Fig. 2. hSIRPa-transgenic mice have improved hematopoiesis upon CD34+
cell engraftment. Irradiated newborn mice were transplanted with CD34+
cells and engraftment was monitored after 10 to 12 wk by FACS. (A) Rep-
resentative staining pattern in the peripheral blood of a hSIRP+ Rag2−/−γc−/−
mouse. (B–E) Frequencies of hCD45+, hCD3+, CD19+, and CD33+SSClow cells in
the blood were compared after engraftment between different immuno-
deﬁcient strains. Data are a summary of at least four experiments with
a total of 60 DKO mice, 63 hSIRPa-DKO mice, 26 NSG mice, and 29 NRG mice.
(F) Representative staining pattern in the bone marrow of a hSIRPa+ Rag2−/−γc−/
− mouse. (G and H) Frequency and number of human CD45+ cells was com-
pared after 12–14 wk between different immunodeﬁcient strains. (I and J)
Numbers of human CD34+ progenitor cells and CD34+CD38− cells were cal-
culated on the basis of total cell number and frequencies determined by
FACS. Data are a summary of three experiments with a total of 22 DKO mice,
24 hSIRPa-DKO mice, and 9 NSG/NRG mice. Data were analyzed by one-way
ANOVA test and individual P values for posttest are displayed. *P < 0.05,
**P < 0.01.
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have important implications for the further development of this
platform for human vaccine development.
Discussion
Severely immunocompromised mice lacking T cells, B cells, and
NK cells have become widely used hosts for the xenotrans-
plantation of human cells due to their diminished rejection of
cells and tissues of human origin (5, 7–9). However, it has been
noted that there are additional strain-speciﬁc factors that inﬂuence
engraftment efﬁciencies as demonstrated by the incapability of
C57Bl6 Rag2−/−γc−/−, in contrast to NOD/Rag1−/−γc−/− mice, to
support engraftment of human cells. The importance of murine
macrophages in xenorejection had been notedmore than 10 y ago,
but the mechanisms of xenorecognition were only described re-
cently (11, 17, 18). It has been established that binding of CD47 on
target cells to SIRPa on macrophages sends a “Don’t eat me”
signal to the phagocyte, i.e., murine CD47−/− cells are rapidly
cleared fromWTmice (14). In the context of xenotransplantation,
the advantage of NOD/scid mice as hosts for human cells com-
pared with CB17/scid or C57Bl6/Rag mice was subsequently
suggested to require a speciﬁc variant of the polymorphic in-
hibitory receptor SIRPa (11). A number of polymorphisms in the
extracellular domain of SIRPa enabled SIRPa (NOD) to bind to
human CD47, whereas SIRPa (C57Bl6) was unable to bind hu-
man CD47 (11). In vitro assays were further used to characterize
the direct effect of SIRPa on human hematopoiesis, but it
remained formally unconﬁrmed whether SIRPa is sufﬁcient for
the enhanced engraftment in NOD-based strains. Notably, the
NOD strain is characterized by a number of well-documented
alterations in immune functions such as complement deﬁciency
and impaired dendritic cell maturation (30). We demonstrate in
this study that transgenic, faithful expression of human SIRPa
in mice is indeed sufﬁcient to strongly decrease rejection of hu-
man cells in Rag2−/−γc−/− on a mixed 129/BALB/c background,
resulting in increased human cell numbers and an increased
functionality of the human adaptive immune system in vivo.
In our initial proof-of-concept experiments to evaluate whether
hSIRPa is functional in transgenic mice, human erythrocytes were
transferred into mice. This approach was chosen because negative
regulation of erythrophagocytosis is highly dependent on the
interaction of CD47 and SIRP (14). Human erythrocytes were
cleared within hours in DKOmice and the decreased clearance of
erythrocytes in hSIRPa-DKO mice compared with DKO mice
indicates that hSIRPa is able to negatively regulate phagocytosis
by murine macrophages and that human erythrocyte clearance is
indeed modulated via CD47–SIRPa interaction. However, not
only phagocytosis of erythrocytes is regulated by this interaction,
as also murine CD47−/− leukocytes are rapidly cleared upon
transfer into WT mice, leading to a failure of CD47−/− cells to
repopulate lethally irradiated mice (21). Moreover, in wild-type
mice, circulating murine HSCs up-regulate CD47 to avoid phago-
cytosis in the spleen, demonstrating a requirement for HSPC
survival (15). In line with these ﬁndings we demonstrated that
expression of hSIRPa in 129/BALB/c Rag2−/−γc−/− mice en-
hanced the efﬁciency of engraftment of human hematopoietic
stem and progenitor cells at two levels. First, the frequency of
mice with detectable human cell engraftment in the peripheral
blood was almost doubled, and second, frequencies of human cell
engraftment were signiﬁcantly increased. In comparison with
NSG mice, hSIRPa-DKO mice were equally well engrafted, but
we observed a slightly increased early mortality (<12 wk) of
engrafted NSG mice, which can likely be attributed to increased
gamma-irradiation sensitivity of scid strains compared with Rag1/
Rag2-deﬁcient strains (Table S1). As a consequence, fewer en-
grafted mice can be used for experiments (DKO, 40%; hSIRPa-
DKO, 70%; and NSG, 53%) (Table S1). Although no formal
survival analysis was performed, we noted that the difference in
survival became larger at later time points (Table S2). In line with
a previous report, we found no NSG mice alive after 9 mo,
impairing the value of this model for long-term studies (28).
Our analysis of hematopoietic organs in the different strains of
mice demonstrate increased numbers of human HSPCs in the
bone marrow of hSIRPa-DKO mice compared with DKO mice.
Striking differences were also visible in the blood and thymus and
spleen with two- to threefold increased cell numbers after 3 mo in
SIRP-DKO mice compared with DKO mice. Interestingly, the
overall composition of the hematopoietic system in the spleen was
similar in DKO, hSIRPa-DKO, and NOD-based mice, indicating
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Fig. 3. Elevated numbers of human cells in the periphery of hSIRPa-
transgenic mice. (A) Representative staining pattern in the spleen of a
hSIRPa+ Rag2−/−γc−/− mouse. (B and C) Frequencies and numbers of total
human CD45+ cells in the spleen were determined after 12–14 wk. (D and E)
At the same time, frequencies and numbers of CD3+ T cells and CD19+ B cells
in the spleen were determined. (F) Representative staining pattern in the
thymus of a hSIRPa+ Rag2−/−γc−/− mouse. (G) Enumeration of the number of
human thymocytes and of (H) CD4+CD8+ thymocytes after 12–14 wk by
combination of FACS staining and total cell count. Data are a summary of
three experiments with a total of 22 DKO mice, 24 hSIRPa-DKO mice, and 9
NSG/NRG mice. Data were analyzed by one-way ANOVA test and individual P
values for posttest are displayed. *P < 0.05, **P < 0.01.
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that hSIRPa expression affects the efﬁciency of initially trans-
ferred stem and progenitor cells to seed the bone marrow and
subsequently differentiate into various lineages of cells. However,
some signiﬁcant differences were observed, which include in-
creased frequencies of CD3−NKp46+ cells in the spleen and
signiﬁcantly increased numbers of CD4+CD8+ double-positive
thymocytes. The latter might be a direct result of decreased
phagocytic activity in this organ, which contains numerous phago-
cytes normally responsible for removing negatively selected thy-
mocytes. Alternatively, this might also be a consequence of in-
creased CD47 signaling in developing T cells as ligation of CD47
sends costimulatory signals (31–33). Another notable difference
was observed when mice were analyzed for the presence of pla-
telets and erythrocytes. Whereas hSIRPa-DKO mice had an in-
creased number of human platelets compared with DKO mice,
they did not reach levels observed in NSG mice. Similarly, fre-
quencies of erythrocytes were signiﬁcantly higher in NSG mice
compared with DKO and hSIRPa-DKO mice. This might be the
result of additional strain-speciﬁc mutations beyond SIRPa that
either favor development or persistence of these cell lineages
in vivo (30). Longitudinal analysis of engraftment in DKO and
hSIRPa-DKO mice revealed that, whereas DKO mostly lost hu-
man cells after 9 mo, they were still routinely detectable in
hSIRPa-DKO mice. This could be mediated either by prolonged
hematopoiesis in the bone marrow or enhanced survival of dif-
ferentiated cells in the peripheral organs of hSRIPa-transgenic
mice. Importantly, the analysis of older mice (∼9 mo postengraft-
ment) revealed one of the shortcomings of current mouse models as
human hematopoietic stem and progenitor cells were almost com-
pletely lost. Hence, we predict that combinations of hSIRPa with
additional human knockins may overcome this limitation.
Recently, several approaches have been used to improve hu-
man cell engraftment and the unbalanced lineage differentiation
in CD34+ cell engraftedmice. These include transient approaches
such as hydrodynamic injection of plasmid DNA (34), injections
of cytokines, and infections of mice or CD34+ cells with lentivi-
ruses (35–37). Alternatively, transgenic expression of human
MHC molecules has been demonstrated to improve the de-
velopment of antigen-speciﬁc immune responses in vivo (38–40).
Nonetheless, overexpression of cytokines might also have detri-
mental side effects due to the unphysiological expression such as
in mice transgenic for SCF, GM-CSF, and IL-3 (41). An alter-
native approach to provide human growth factors in vivo is to
genetically engineer mice and replace the mouse genes with their
human counterparts resulting in their expression in the appro-
priate niche at physiological levels. Indeed, faithful replacement
of mouse GM-CSF and IL-3 as well as thrombopoietin (TPO)
by our group has resulted in improved development of human
macrophages in the lung and HSC and HPC maintenance in
the bone marrow, respectively (23, 24). Notably, in human TPO
knockinmice, despite a highly increased engraftment level of stem
and progenitor cells in the bone marrow, no changes were ob-
served in the periphery, demonstrating the existence of limiting
factors in the periphery such as destruction by phagocytes. With
the hSIRPa-DKOmice, we have generated a strain that combines
superior engraftment level and the possibility of long-term genetic
manipulations to further enhance the murine host.
A highly desired application of mice with functional human
immune systems is the development and testing of human vac-
cines. However, the induction of immune responses in vivo has
been relative inefﬁcient so far (5, 7–9, 29). Several studies have
reported pathogen-speciﬁc immune responses upon infection.
Although it was reported that around 50% of mice produced
virus-speciﬁc IgM and IgG upon dengue virus infection (42),
other studies reported frequencies below 20% of mice producing
antigen-speciﬁc IgM and IgG after HIV and EBV infection
(29, 43). Upon immunization with adjuvant and antigen, class
switching of antigen-speciﬁc immunoglobulins is similarly in-
efﬁcient as only a fraction of immunized animals show antigen-
speciﬁc IgG responses (5, 7–9, 44, 45). These studies included
NSG and BALB/c DKO mice and different adjuvant/antigen
combinations. At this point it remains open why antibody pro-
duction is limited, but because B cells from humanized mice
respond normally in vitro, it indicates that the human immune
system provides only inefﬁcient help in vivo (44). In hSIRPa-
DKO mice, immunization with a T cell-dependent antigen in-
duced stronger immune responses as measured by higher titers
of antigen-speciﬁc IgM compared with DKO mice. Furthermore,
more hSIRPa+ mice produced antigen-speciﬁc IgG. To provide
help for B cells, antigen-speciﬁc T cells need to recognize anti-
gens presented in the context of MHC molecules. Hence, the
increased functionality in SIRP-DKO mice is likely the result of
improved selection and differentiation of T cells in vivo due to
overall higher numbers of human immune cells. Similarly, HLA-
DR4 transgenic mice and humanized mice that are generated by
cotransplantation of CD34+ cells and human fetal thymus pieces
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Fig. 4. Improved humoral antigen-speciﬁc immune
responses in hSIRPa-transgenic mice. Characterization
of humoral immune responses before (A–C) and after
(D–I) immunization. (A and B) Total serum levels of
human IgM (A) and IgG (B) were determined by ELISA
in Rag2−/−γc−/− (−hSIRPa, n = 28) and hSIRPa-transgenic
Rag2−/−γc−/− (+hSIRPa, n = 30) mice. (C) The frequencies
of human IgG-producing cells in the spleen were
measured using ELISPOT without immunization. (D–I)
Mice were immunized with OVA/CFA and boosted 14
d later with OVA/IFA. (D–G) Anti-OVA IgM (D and E)
and IgG (G and H) were assayed by ELISA and OD450 nm
readings are displayed for serial dilution of serum from
individual DKO (D and F) or hSIRPa-DKO (G and H)
mice. (F and I) OD450 nm readings for a serum dilution
of 1:33 are shown; each dot represents a mouse from
one experiment. Data were analyzed using Mann-
Whitney test, *P < 0.05.
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have improved HLA-restricted T cell responses and also improved
antigen-speciﬁc antibody responses (40, 46). However, further
studies will be needed to characterize and quantify antigen-
speciﬁc T cell responses in hSIRPa-DKO mice.
In summary, we achieved improved frequencies of engrafted
mice and increased levels of engraftment of human cells by
transgenic expression of hSIRPa in 129/BALB/c Rag2−/−γc−/−
mice, resulting in an improved functionality of the human im-
mune system in vivo. Supporting our ﬁnding of the central
function of CD47-SIRPa is a study by Legrand et al. (47). Using
lentiviral transduction of human HSPCs with mouse CD47 and
breeding of NOD-SIRPa to BALB/c Rag2−/−γc−/− mice, they
demonstrate similar quantitative and qualitative improvements
of the human immune system in vivo. Genetic engineering in
our strain can be used to rapidly generate mice expressing genes
of interest and analyze their inﬂuence on engraftment of human
tissues and cells. On the basis of our successful completion of
diverse genetic modiﬁcations such as the replacement of com-
plete mouse genes with their human counterparts and expres-
sion of human genes using BAC transgenes, we believe that this
approach enables targeted modiﬁcations to further improve the
murine host for transplantation of human tissues and cells.
Materials and Methods
Generation of Human SIRPa-Transgenic Mice. hSIRPa-transgenic mice were
generated by transgenesis using a BAC containing the entire 45-kb SIRPa
gene along with ∼51 kb of ﬂanking DNA on the 5′ end and 78 kb on the 3′
end that was manipulated to contain a hygromycin resistance cassette. F1
129/Balbc Rag2+/−γcy/− ES cells were electroporated and selected using
hygromycin. Positive colonies were screened by PCR to map whether the full-
length BAC had been integrated. Further details can be found in SI Materials
and Methods.
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